Profile data is unavailable for this security.
About the company
Aptevo Therapeutics Inc. is a clinical-stage biotechnology company. It is focused on developing novel immunotherapy candidates for the treatment of different forms of cancer. It has developed two versatile and enabling platform technologies for rational design of precision immune modulatory drugs. Its lead clinical candidates, APVO436 and ALG.APV-527, and preclinical candidates, APVO603 and APVO711, are developed using its ADAPTIR modular protein technology platform. Its preclinical candidate APVO442 is developed using its ADAPTIR-FLEX modular protein technology platform. APVO436 is a bispecific ADAPTIR that is designed to engage CD3 and CD123 to redirect T-cells to destroy leukemia cells expressing the target CD123 molecule on their surface. ALG.APV-527 is a novel investigational bispecific ADAPTIR candidate. APVO603 is a preclinical dual agonist bispecific ADAPTIR candidate designed to simultaneously target 4-1BB (CD137) and OX40 (CD134), both members of the TNF-receptor family.
- Revenue in USD (TTM)0.00
- Net income in USD-27.31m
- Incorporated2016
- Employees40.00
- LocationAptevo Therapeutics Inc2401 4th Ave Ste 1050SEATTLE 98121-3460United StatesUSA
- Phone+1 (206) 838-0500
- Fax+1 (206) 838-0503
- Websitehttp://aptevotherapeutics.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Petros Pharmaceuticals Inc | 4.69m | -20.46m | 3.21m | 21.00 | -- | 0.3221 | -- | 0.6831 | -7.37 | -7.37 | 1.68 | 1.55 | 0.1542 | 0.7858 | 2.15 | 223,487.10 | -29.37 | -32.43 | -41.80 | -68.05 | 69.91 | 62.04 | -190.50 | -201.70 | 1.46 | -- | 0.4284 | -- | -2.83 | -16.15 | 31.06 | -- | -- | -- |
| NovaBay Pharmaceuticals Inc | 14.23m | -18.43m | 3.26m | 24.00 | -- | -- | -- | 0.229 | -108.80 | -108.97 | 50.49 | 0.1749 | 1.41 | 2.91 | 11.08 | 593,041.70 | -108.92 | -61.51 | -185.74 | -83.89 | 54.47 | 59.99 | -77.22 | -86.47 | 0.7462 | -- | 0.8629 | -- | 2.24 | 3.32 | -2.66 | -- | -15.46 | -- |
| TRACON Pharmaceuticals Inc | 12.15m | 1.75m | 3.27m | 17.00 | 1.87 | -- | 1.85 | 0.2691 | 0.6509 | 0.6509 | 6.27 | -0.6618 | 1.37 | -- | -- | 714,411.80 | 19.78 | -79.42 | -- | -177.85 | -- | -- | 14.39 | -813.81 | -- | -0.4613 | -- | -- | -- | 32.05 | 87.68 | -- | -- | -- |
| Gold River Productions Inc. | -100.00bn | -100.00bn | 3.30m | 1.00k | -- | 5.09 | -- | -- | -- | -- | -- | 0.0005 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -100.11 | -- | -- | -- |
| Altamira Therapeutics Ltd | 118.07k | -8.14m | 3.34m | 10.00 | -- | 0.3045 | -- | 28.27 | -31.58 | -26.66 | 0.2403 | 4.89 | 0.0151 | 34.05 | 32.30 | 11,806.78 | -103.88 | -73.80 | -6,364.67 | -123.19 | -87.90 | -- | -6,892.99 | -- | 1.38 | -4.36 | 0.0152 | -- | -- | -- | 61.02 | -- | -- | -- |
| Aditxt Inc | 506.45k | -41.45m | 3.35m | 47.00 | -- | 0.3371 | -- | 6.61 | -109.80 | -109.80 | 0.7488 | 5.96 | 0.0284 | 0.9296 | 1.34 | 10,775.53 | -231.82 | -192.78 | -658.00 | -321.59 | -27.22 | -- | -8,149.75 | -7,208.65 | 0.0562 | -3.42 | 0.3915 | -- | -30.90 | -- | -18.11 | -- | -- | -- |
| Livewire Ergogenics Inc | 67.98k | -1.09m | 3.35m | 1.00 | -- | -- | -- | 49.25 | -0.0061 | -0.0061 | 0.0003 | -0.0022 | 0.1979 | 1.74 | 2.86 | 67,980.00 | -317.45 | -- | -- | -- | -113.70 | -- | -1,604.38 | -- | 0.1248 | -2.13 | -- | -- | 68.58 | -- | -3.64 | -- | -- | -- |
| Manuka Inc | 671.00k | -1.14m | 3.36m | 4.00 | -- | -- | -- | 5.01 | -0.0128 | -0.0128 | 0.0066 | -0.0124 | 2.41 | 0.9412 | 37.28 | 167,750.00 | -410.43 | -463.75 | -- | -- | 88.08 | -- | -170.04 | -732.15 | 0.0194 | -- | -- | -- | -- | -- | -854.23 | -- | -- | -- |
| Silo Pharma Inc | 72.12k | -3.53m | 3.36m | 3.00 | -- | 0.6425 | -- | 46.65 | -1.18 | -1.20 | 0.024 | 1.87 | 0.008 | -- | -- | 24,040.00 | -39.26 | -24.90 | -43.11 | -26.39 | 91.90 | 82.79 | -4,889.57 | -2,757.85 | -- | -- | 0.00 | -- | 0.00 | -- | 7.07 | -- | -- | -- |
| Aptevo Therapeutics Inc | 0.00 | -27.31m | 3.39m | 40.00 | -- | 0.0916 | -- | -- | -98.49 | -97.90 | 0.00 | 9.06 | 0.00 | -- | -- | 0.00 | -103.85 | -47.16 | -134.86 | -85.03 | -- | -- | -- | -583.47 | -- | -- | 0.00 | -- | -100.00 | -- | -365.90 | -- | -- | -- |
| Clearmind Medicine Inc | 0.00 | -8.09m | 3.39m | -- | -- | 0.6727 | -- | -- | -30.92 | -30.92 | 0.00 | 1.59 | 0.00 | -- | -- | -- | -109.55 | -218.20 | -180.61 | -488.96 | -- | -- | -- | -- | -- | -2.90 | 0.0184 | -- | -- | -- | -25.03 | -- | -- | -- |
| 60 Degrees Pharmaceuticals Inc | 378.20k | -1.07m | 3.49m | 2.00 | -- | -- | -- | 9.23 | -0.1563 | -0.1563 | 0.0564 | 0.6121 | 0.0474 | 0.8827 | 1.90 | 126,066.70 | -9.87 | -- | -- | -- | -23.45 | -- | -208.43 | -- | 6.77 | -- | 0.0217 | -- | -50.40 | -- | 35.51 | -- | -- | -- |
| Biostax Corp | 0.00 | -1.57m | 3.56m | -- | -- | -- | -- | -- | -0.0188 | -0.0188 | 0.00 | -0.058 | 0.00 | -- | -- | -- | -390.77 | -81.51 | -- | -- | -- | -- | -- | -- | -- | -6.05 | -- | -- | -- | -- | 53.32 | -- | -- | -- |
| Eiger Biopharmaceuticals Inc | 15.77m | -74.96m | 3.57m | 25.00 | -- | -- | -- | 0.2263 | -50.80 | -50.80 | 10.69 | -9.77 | 0.1985 | 0.0064 | 9.19 | 630,920.00 | -94.31 | -60.25 | -186.10 | -76.51 | 99.91 | -- | -475.26 | -823.59 | 0.6809 | -22.03 | 1.54 | -- | 16.98 | -- | 22.54 | -- | 10.51 | -- |
| Avenue Therapeutics Inc | 0.00 | -7.18m | 3.59m | 3.00 | -- | 0.7929 | -- | -- | -39.36 | -39.36 | 0.00 | 4.81 | 0.00 | -- | -- | 0.00 | -123.08 | -186.91 | -1,045.52 | -287.70 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -192.15 | -- | -- | -- |
Data as of Jun 07 2024. Currency figures normalised to Aptevo Therapeutics Inc's reporting currency: US Dollar USD
0.18%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Tower Research Capital LLCas of 31 Mar 2024 | 1.32k | 0.08% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 890.00 | 0.06% |
| Andbank Wealth Management SGIIC SAUas of 31 Dec 2023 | 318.00 | 0.02% |
| Morgan Stanley & Co. LLCas of 31 Mar 2024 | 130.00 | 0.01% |
| Qube Research & Technologies Ltd.as of 31 Mar 2024 | 100.00 | 0.01% |
| Morgan Stanley Smith Barney LLC (Investment Management)as of 31 Mar 2024 | 64.00 | 0.00% |
| Osaic Wealth, Inc. (Investment Management)as of 31 Mar 2024 | 45.00 | 0.00% |
| JPMorgan Securities LLC (Investment Management)as of 31 Mar 2024 | 43.00 | 0.00% |
| Wells Fargo Advisors Financial Network LLCas of 31 Mar 2024 | 32.00 | 0.00% |
| Fifth Third Bank, NA (Investment Management)as of 31 Mar 2024 | 6.00 | 0.00% |
More ▼
Data from 31 Jan 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
